Cite
HARVARD Citation
Ma, W. et al. (n.d.). 2365 Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies. European journal of cancer. pp. S458-. [Online].